Clinical Trials Logo

Common Warts clinical trials

View clinical trials related to Common Warts.

Filter by:
  • None
  • Page 1

NCT ID: NCT03166137 Not yet recruiting - Common Warts Clinical Trials

Carbon Dioxide Laser and Cryotherapy in Treatment of Warts

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Viral warts are common skin conditions seen in both children and adults. Human papilloma virus is responsible for verrucae. Cutaneous manifestation of the human papillomavirus, are extremely common particularly on the hands and feet. Warts can induce hard, thickened skin, black pinpoints, pain or tenderness with significant morbidity for the patients.

NCT ID: NCT02798419 Completed - Common Warts Clinical Trials

Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts

Start date: January 2016
Phase: Phase 2
Study type: Interventional

DFD05 vs. Active01 in the treatment of common warts

NCT ID: NCT02748902 Completed - Verruca Vulgaris Clinical Trials

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

Start date: April 27, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if ingenol mebutate 0.05% gel is safe and effective in treating common warts on the hands.

NCT ID: NCT02669862 Completed - Common Warts Clinical Trials

A Study of A-101 Solution in Subjects With Common Warts.

Start date: December 21, 2015
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment groups.

NCT ID: NCT02650466 Completed - Common Warts Clinical Trials

Nanopulse Efficacy Study for the Treatment of Common Warts

Start date: December 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the Nanopulse System can be used to clear common wart lesions on the skin. The Nanopulse System uses a series of low energy, high voltage pulses, each one several billionths of a second in duration, to effectively kill the target tissue contained within the applicator tip electrodes with minimal damage to surrounding tissue. Efficacy and patient outcomes are expected to equal or surpass current treatment modalities in terms of increased ease of use, faster patient healing and minimal scarring with fewer complications resulting from treatment. The device emits significantly less energy than existing electro-surgery or electro-cautery equipment and is believed to be similar to laser therapy treatment of warts. Trained clinicians can usually diagnose warts based by their appearance and location . Non-genital warts are subcategorized into common, periungual, flat, filiform, and plantar types. Common warts are benign, often skin-colored, or brown-grey, rough, bumpy growths on the hands and feet (caused by Human Papilloma Virus type 2) . Common warts in individuals without any immune deficiencies are low risk and are the focus of this study.Based upon the preclinical profile of the Nanopulse device, particularly its safety profile and its effect on transformed cells, it is hypothesized that application of pulses from the Nanopulse System , will result in complete clinical clearance of Common Wart lesions with minimal scarring.

NCT ID: NCT02640820 Active, not recruiting - Common Warts Clinical Trials

Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

Start date: December 2015
Phase: Phase 2
Study type: Interventional

Warts are benign epidermal tumors caused by human papillomaviruses (HPVs). The active pharmaceutical ingredient DPCP has been used for many years as a compounded formulation in acetone for the treatment of warts, alopecia areata and more recently, cutaneous metastatic melanoma lesions. An improved topical ointment formulation of DPCP called Samcyprone™ will be evaluated for the treatment of common warts.

NCT ID: NCT01286441 Completed - Common Warts Clinical Trials

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts

Start date: November 2012
Phase: Phase 2
Study type: Interventional

Nonclinical studies have shown sandalwood oil to have anti-inflammatory, anti-fungal, antiviral, and anti-bacterial activities. Previous clinical studies have shown East Indian Sandalwood oil to be promising as a treatment for common warts in adults and children. The primary objective of this study is to evaluate the efficacy and safety of 10%, 20%, and 30% East Indian Sandalwood Oil (EISO) ointment compared with the ointment placebo administered twice daily (bid) for 12 weeks for the treatment of common warts (Verruca vulgaris).